Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
Clozapine is an atypical antipsychotic with affinity for a broad range of receptors, including serotonin (5-HT) and dopamine receptors. It is successful in treating about 60% of patients refractory to other antipsychotic drugs. Since genetic variation in clozapine's neurotransmitter receptor targets may affect clinical response through altering drug binding or receptor expression, we have studied a His452Tyr polymorphism in the 5-HT2A receptor (HTR2A) in a sample of 153 schizophrenic patients undergoing clozapine treatment and 178 normal controls. An association was found between the allele Tyr452 and poor clinical response.
Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK. marranzc@hgmp.mrc.ac.uk
M J
MJ
Arranz
D A
DA
Collier
J
J
Munro
P
P
Sham
G
G
Kirov
M
M
Sodhi
G
G
Roberts
J
J
Price
R W
RW
Kerwin
D000483:Alleles; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003024:Clozapine / Q000494:pharmacology* / Q000627:therapeutic use; D004247:DNA / Q000032:analysis; D005838:Genotype; D006801:Humans; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales; D011985:Receptors, Serotonin / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D014150:Antipsychotic Agents; D011985:Receptors, Serotonin; D004247:DNA; D003024:Clozapine